GSK begins Oxford colitis trial: RBC keeps target for GSK stock

Published on 10/15/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC kept its GBp 1,975 target on October 13, 2026. GSK stock faces October 28 results after GBP 8.41 billion second-quarter turnover.

Pipeline and reporting dates

GSK and Oxford University dosed the first patient in a colitis trial on October 14, 2026.
Second-quarter turnover reached GBP 8.41 billion, up 5.00 percent at constant exchange rates.
GSK stock was trading at EUR 21.50 at 11:03 a.m. CEST at Lang & Schwarz on October 15, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) and Oxford University dosed the first patient in an early-stage ulcerative colitis treatment trial on October 14, 2026, according to MarketBeat. The same announcement placed GSK's pipeline activity alongside an $800 million Pennsylvania manufacturing plan, while RBC retained a GBp 1,975 target ahead of the October 28 results, as reported by Proactive Investors on October 13, 2026.

Colitis trial adds a pipeline marker

The trial is an early-stage program, so its immediate financial contribution is limited. Its significance lies in the breadth of GSK's immunology pipeline, which is being developed alongside vaccines, HIV medicines and respiratory treatments.

GSK's Pennsylvania plan involves more than USD 800 million and is expected to create 300 jobs, according to MarketBeat's October 14, 2026 report. The investment points to manufacturing capacity as a second strategic theme beside clinical development.

What will results test?

RBC expects third-quarter revenue of GBP 8.82 billion, compared with GBP 8.89 billion consensus, and forecasts core earnings per share of GBp 50.80 in its October 13, 2026 assessment. The broker sees vaccine revenue at GBP 2.61 billion, while HIV revenue is forecast at GBP 2.14 billion and Nucala revenue at GBP 623.00 million.

Three dated steps for investors

On July 28, 2026, GSK reported second-quarter revenue of GBP 8.41 billion, up 5.00 percent at constant exchange rates, with core operating profit of GBP 2.80 billion, up 7.00 percent, according to Quiver Quantitative. On September 18, 2026, GSK directors bought 1,500 ordinary shares, according to a filing published by the SEC. On October 14, 2026, GSK and Oxford University dosed the first patient in the colitis trial.

Upcoming dates set the near-term frame

GSK's next reported date is October 26, 2026, when a US regulatory decision is expected for hepatitis B treatment bepirovirsen. The company is also scheduled for an oncology investor update on October 27, 2026, before the third-quarter results on October 28, 2026, according to Proactive Investors.

Stock price on October 15

GSK stock was trading at EUR 21.50 at Lang & Schwarz on October 15, 2026, at 11:03 a.m. CEST. The price gives investors a dated euro-market reference ahead of the three October events.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.